Analysts Set Generation Bio Co. (NASDAQ:GBIO) Price Target at $8.88

Generation Bio Co. (NASDAQ:GBIO) has earned an average rating of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $8.8750.

A number of brokerages have recently weighed in on GBIO. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a report on Thursday, January 22nd. Zacks Research raised Generation Bio to a “hold” rating in a report on Monday, January 26th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of Generation Bio in a research note on Friday, November 7th. Citigroup reaffirmed a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th. Finally, Wedbush set a $5.50 price objective on Generation Bio and gave the company an “outperform” rating in a report on Tuesday, December 16th.

Generation Bio Stock Performance

GBIO stock opened at $5.34 on Friday. The company’s 50 day moving average price is $5.51 and its 200 day moving average price is $5.68. The firm has a market capitalization of $35.99 million, a price-to-earnings ratio of -0.57 and a beta of 2.05. Generation Bio has a fifty-two week low of $3.00 and a fifty-two week high of $8.20.

Institutional Trading of Generation Bio

Several institutional investors have recently modified their holdings of GBIO. Geode Capital Management LLC raised its position in Generation Bio by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 51,795 shares of the company’s stock valued at $294,000 after purchasing an additional 1,990 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in Generation Bio in the fourth quarter valued at $31,000. Shay Capital LLC purchased a new stake in shares of Generation Bio in the third quarter valued at about $64,000. ADAR1 Capital Management LLC purchased a new stake in shares of Generation Bio in the third quarter valued at about $136,000. Finally, Torno Capital LLC acquired a new stake in shares of Generation Bio during the fourth quarter worth about $142,000. Hedge funds and other institutional investors own 95.22% of the company’s stock.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.